
GoodRx Holdings (NASDAQ:GDRX), a prescription savings platform in the U.S., has released its latest Weight Loss Medications Tracker, revealing a sharp increase in the use of popular weight loss drugs like Eli Lilly And Co’s (NYSE:LLY) Mounjaro and Zepbound, and Novo Nordisk A/S’ (NYSE:NVO) Ozempic and Wegovy.
Despite limited insurance coverage and high out-of-pocket costs, demand for these medications is soaring.